ES2690554T3 - Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas - Google Patents

Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas Download PDF

Info

Publication number
ES2690554T3
ES2690554T3 ES15177122.7T ES15177122T ES2690554T3 ES 2690554 T3 ES2690554 T3 ES 2690554T3 ES 15177122 T ES15177122 T ES 15177122T ES 2690554 T3 ES2690554 T3 ES 2690554T3
Authority
ES
Spain
Prior art keywords
cells
polypeptide
cell
inhibitor
pluripotent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15177122.7T
Other languages
English (en)
Spanish (es)
Inventor
Yan Shi
Caroline Desponts
Sheng Ding
Hongyan Zhou
Tongxiang Lin
Wenlin Li
Saiyong Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of ES2690554T3 publication Critical patent/ES2690554T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
    • C12N2506/094—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells from keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
ES15177122.7T 2008-03-17 2009-03-17 Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas Active ES2690554T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6995608P 2008-03-17 2008-03-17
US69956P 2008-03-17
US19798608P 2008-10-31 2008-10-31
US197986P 2008-10-31

Publications (1)

Publication Number Publication Date
ES2690554T3 true ES2690554T3 (es) 2018-11-21

Family

ID=41091504

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15177122.7T Active ES2690554T3 (es) 2008-03-17 2009-03-17 Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas

Country Status (15)

Country Link
US (8) US9534205B2 (enExample)
EP (4) EP3409762A1 (enExample)
JP (7) JP5951254B2 (enExample)
KR (1) KR101679082B1 (enExample)
CN (2) CN104694570B (enExample)
AU (1) AU2009225665B9 (enExample)
BR (1) BRPI0908708A2 (enExample)
CA (1) CA2718904C (enExample)
ES (1) ES2690554T3 (enExample)
IL (1) IL208144B (enExample)
MX (1) MX2010010165A (enExample)
RU (1) RU2010139426A (enExample)
SG (4) SG10201607710UA (enExample)
WO (1) WO2009117439A2 (enExample)
ZA (1) ZA201006683B (enExample)

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171185A1 (en) * 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
CA2659945C (en) * 2005-08-03 2014-12-16 Advanced Cell Technology, Inc. Improved methods of reprogramming animal somatic cells
IN2014DN06624A (enExample) 2005-10-18 2015-07-10 Univ Colorado
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101864392B (zh) * 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
EP2626416A3 (en) 2007-04-07 2013-12-18 The Whitehead Institute for Biomedical Research Reprogramming of somatic cells
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US20140342984A1 (en) * 2007-10-19 2014-11-20 Robert G. Matheny Compositions for Regenerating Defective or Absent Myocardium
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
EP2276838A4 (en) * 2008-04-07 2012-02-01 Nupotential Inc RE-PROGRAMMING A CELL BY INDUCING A PLURIPOTENTIC GENE THROUGH RNA INTERFERENCE
CN101855350B (zh) 2008-05-02 2014-12-31 国立大学法人京都大学 核重编程序方法
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9497943B2 (en) 2008-06-13 2016-11-22 Whitehead Institute For Biomedical Research Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides
CA2731767C (en) 2008-07-21 2016-12-06 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
EP2376626A4 (en) 2008-12-13 2012-10-17 Dna Microarray MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS)
JP6093110B2 (ja) 2008-12-17 2017-03-08 ザ スクリプス リサーチ インスティテュート 幹細胞の作製と維持
EP2379577A4 (en) * 2008-12-23 2012-08-29 Vivoscript Inc COMPOSITIONS AND METHODS FOR CELL REPROGRAMMING WITHOUT GENETIC MODIFICATION
EP2414510A4 (en) * 2009-04-03 2013-04-17 Mclean Hospital Corp INDUCED PLURIPOTENTIAL STEM CELLS
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
WO2010137348A1 (en) 2009-05-29 2010-12-02 Keio University Method for selecting clone of induced pluripotent stem cells
US8709805B2 (en) * 2009-08-07 2014-04-29 Kyoto University Canine iPS cells and method of producing same
AU2014250681B2 (en) * 2009-10-16 2016-12-15 The Scripps Research Institute Induction of pluripotent cells
US9005968B2 (en) * 2009-10-16 2015-04-14 The Scripps Research Institute Induction of pluripotent cells
EP2494032A4 (en) * 2009-10-29 2013-06-05 Univ Mcmaster GENERATION OF INDUCED PLURIPOTENTER STEM CELLS AND FIBROBLAST PRECURSOR CELLS
DK2494039T3 (da) * 2009-10-31 2019-08-19 Genesis Tech Limited Fremgangsmåder til reprogrammering af celler og anvendelser deraf
JP5898086B2 (ja) * 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 化学物質を用いるエピソームリプログラミング
WO2011082038A2 (en) * 2009-12-31 2011-07-07 Fate Therapeutics, Inc. Improved reprogramming compositions
US20130059385A1 (en) * 2010-03-02 2013-03-07 The Scripps Research Institute Methods of generating pluripotent stem cells
EP2366432A1 (en) * 2010-03-16 2011-09-21 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of glycogen synthase kinase 3 for use in therapeutic methods and screening method relating thereto
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
CN102260646B (zh) * 2010-05-26 2015-09-16 北京瑞普晨创科技有限公司 一种制备诱导多潜能干细胞的方法,试剂盒及用途
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
EP2582792B1 (en) 2010-06-18 2018-10-31 FUJIFILM Cellular Dynamics, Inc. Cardiomyocyte medium with dialyzed serum
WO2012007725A2 (en) * 2010-07-16 2012-01-19 Plasticell Ltd Method of reprogramming a cell
JP2013536689A (ja) 2010-09-01 2013-09-26 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Ｅｍｔを調節するための組成物および方法ならびにその使用
US20120064041A1 (en) * 2010-09-03 2012-03-15 Arshak Alexanian Efficient Generation of Neurally-Induced Mesenchymal Stem Cells and Applications Thereof
JP5794588B2 (ja) * 2010-09-14 2015-10-14 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
WO2012040295A2 (en) * 2010-09-22 2012-03-29 The Regents Of The University Of Colorado Therapeutic applications of smad7
JP6002675B2 (ja) * 2010-12-17 2016-10-05 ビオラミナ アーベー 細胞培養培地
AU2011349446C1 (en) 2010-12-22 2016-01-21 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
CA2823154A1 (en) * 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
WO2012098260A1 (en) * 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
EP2705143B1 (en) * 2011-05-02 2021-02-17 Wayne State University A protein-induced pluripotent cell technology uses thereof
US20130064799A1 (en) * 2011-06-01 2013-03-14 Tariq M. Rana Methods for promoting cell reprogramming
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
WO2013013105A2 (en) * 2011-07-19 2013-01-24 Vivoscript,Inc. Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage
CN103703130A (zh) 2011-07-25 2014-04-02 国立大学法人京都大学 筛选诱导的多能干细胞的方法
WO2013058403A1 (ja) 2011-10-21 2013-04-25 国立大学法人京都大学 層流による多能性維持単一分散細胞培養法
US20140329317A1 (en) 2011-11-25 2014-11-06 Kyoto University Method for culturing pluripotent stem cell
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
RU2691027C2 (ru) 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
WO2013131000A1 (en) * 2012-03-01 2013-09-06 Whitehead Institute For Biomedical Research Emt-inducing transcription factors cooperate with sox9
WO2013138623A1 (en) * 2012-03-14 2013-09-19 Children's Medical Center Corporation High-throughput image-based chemical screening in zebrafish blastomere cell culture
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10357517B1 (en) * 2012-10-01 2019-07-23 University Of South Florida Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592
EP2914728B1 (en) 2012-11-01 2020-07-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
EP2914298B1 (en) * 2012-11-02 2020-01-08 Duke University Inhibition of histone methyltransferase for cardiac reprogramming
JP6509126B2 (ja) 2013-01-09 2019-05-08 インターナショナル ステム セル コーポレイション 皮膚の再生を促進する小分子
US20160002599A1 (en) 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
EP2966163B1 (en) 2013-03-06 2018-01-17 Kyoto University Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
CA2904329C (en) 2013-03-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Ptd-smad7 therapeutics
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) * 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10519421B2 (en) 2013-03-21 2019-12-31 Kyoto University Induction of motor neurons from pluripotent stem cells
US10072242B2 (en) 2013-03-25 2018-09-11 Foundation For Biomedical Research And Innovation At Kobe Cell sorting method
KR20140121317A (ko) * 2013-04-06 2014-10-15 서울대학교산학협력단 비신경 세포로부터 유도 신경 줄기 세포의 생산 방법 및 이에 의하여 생산되는 유도 신경 줄기 세포
CA2909230C (en) 2013-04-12 2021-06-15 Kyoto University Method for inducing alveolar epithelial progenitor cells
JP6429280B2 (ja) 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
KR101870174B1 (ko) 2013-05-31 2018-06-22 아이하트 재팬 가부시키가이샤 하이드로겔을 포함하는 적층화된 세포 시트
CA2915085C (en) 2013-06-11 2021-04-27 Kyoto University Method for producing renal progenitor cells and drug comprising the same
CN104278008B (zh) * 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
KR101655383B1 (ko) * 2013-07-27 2016-09-08 고려대학교 산학협력단 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
CN105849255A (zh) 2013-09-05 2016-08-10 国立大学法人京都大学 新的产多巴胺神经前体细胞诱导方法
CN104419683A (zh) * 2013-09-10 2015-03-18 中国科学院生物物理研究所 制备范可尼贫血症患者自体诱导多能干细胞的方法及其应用
EP3060649A4 (en) * 2013-10-23 2017-07-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
JP6415582B2 (ja) 2013-10-25 2018-10-31 ウェイン ステート ユニバーシティー タンパク質誘導生体内細胞リプログラミングによる細胞転換に関する方法、システム、及び組成物
KR102219743B1 (ko) 2013-11-01 2021-02-23 고쿠리츠 다이가쿠 호진 교토 다이가쿠 신규 연골 세포 유도 방법
US9512406B2 (en) 2013-12-20 2016-12-06 The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone Generating hepatocytes
CN105940110A (zh) 2014-01-31 2016-09-14 菲克特生物科学股份有限公司 用于核酸产生和递送的方法和产品
CN104894060B (zh) * 2014-03-03 2018-11-06 中国科学院上海生命科学研究院 诱导体细胞转分化为神经干细胞的方法及其应用
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
JP7012432B2 (ja) 2014-07-14 2022-01-28 中外製薬株式会社 タンパク質のエピトープを同定するための方法
US20170211091A1 (en) * 2014-07-16 2017-07-27 Fundación Pública Andaluza Progreso Y Salud Methods for generating induced pluripotent stem cells
SG10201900323SA (en) 2014-07-18 2019-02-27 Univ Kyoto Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
US20160030484A1 (en) 2014-08-04 2016-02-04 University Of Kansas Mammalian pluripotent stem cells, methods for their production, and uses thereof
RU2565548C1 (ru) * 2014-08-05 2015-10-20 Дмитрий Андреевич Журавлёв Способ получения плюрипотентных стволовых клеток
WO2016022930A1 (en) 2014-08-07 2016-02-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Reversible stencils for fabricating micro-tissues
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2016104717A1 (ja) 2014-12-26 2016-06-30 国立大学法人京都大学 肝細胞誘導方法
WO2016117139A1 (ja) * 2015-01-20 2016-07-28 タカラバイオ株式会社 神経系細胞の製造方法
EP3250682A4 (en) 2015-01-26 2018-08-01 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
JP2018509890A (ja) * 2015-01-30 2018-04-12 センター ナショナル ド ラ ルシェルシュ サイエンティフィーク 人工多能性幹細胞（ｉＰＳＣ）の生産を再プログラムする方法
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2016131137A1 (en) 2015-02-17 2016-08-25 University Health Network Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes
EP3081638A1 (en) 2015-04-16 2016-10-19 Kyoto University Method for producing pseudo-islets
KR20180033537A (ko) 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도
KR102737833B1 (ko) * 2015-08-21 2024-12-03 교토후고리츠다이가쿠호진 골아세포 및 이의 제조 방법
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
CN109072183B (zh) * 2015-10-21 2023-01-20 京都府公立大学法人 细胞的制备方法
JP7063624B2 (ja) * 2016-01-08 2022-05-09 エヴィア ライフ サイエンシズ インコーポレイテッド 低分子化合物による成熟肝細胞からの肝幹／前駆細胞の作製方法
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
SG11201805186VA (en) 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3405568A4 (en) 2016-01-20 2019-12-04 Fate Therapeutics, Inc. COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
WO2017179720A1 (ja) 2016-04-15 2017-10-19 国立大学法人京都大学 Ｃｄ８陽性ｔ細胞を誘導する方法
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
CN105943526B (zh) * 2016-05-18 2018-08-14 上海交通大学医学院附属上海儿童医学中心 Pd0325901在维持动脉导管开放中的应用
EP3483262B1 (en) * 2016-06-03 2021-11-17 Institue of Transfusion Medicine, Academy of Military Medical Sciences, People's Liberation Army of China Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application
WO2018005799A1 (en) * 2016-06-29 2018-01-04 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
WO2018079714A1 (ja) * 2016-10-28 2018-05-03 国立研究開発法人国立がん研究センター ヒト肝前駆細胞の調製方法
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
EP3564385A4 (en) 2016-12-27 2020-08-12 Sumitomo Chemical Company, Limited ASSESSMENT AND SELECTION PROCEDURE FOR INDUCED PLURIPOTENT STEM CELLS, AND PROCESS FOR MANUFACTURING INDUCED PLURIPOTENT STEM CELLS
CN106754655B (zh) * 2016-12-29 2020-06-19 赛业（苏州）生物科技有限公司 一种动物胚胎培养基
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
US12006512B2 (en) 2017-01-20 2024-06-11 Kyoto University Method for producing CD8alpha+beta+ cytotoxic t cells
EP3575392A4 (en) 2017-01-26 2020-08-26 Osaka University MEDIUM INTENDED TO INDUCE DIFFERENTIATION OF STEM CELLS INTO MESODERMAL CELLS AND PROCESS INTENDED TO PRODUCE MESODERMAL CELLS
JP7171055B2 (ja) 2017-03-14 2022-11-15 国立大学法人京都大学 多能性幹細胞からヘルパーｔ細胞を製造する方法
EP3633026A4 (en) 2017-05-25 2021-03-10 Kyoto University METHOD FOR INDUCING THE DIFFERENTIATION OF A MESODERMAL INTERMEDIATE CELL TO A KIDNEY PRECURSOR CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF A PLURIPOTENT STEM CELL FROM A KIDNEY PRECURSOR CELL
WO2018235583A1 (ja) 2017-06-19 2018-12-27 公益財団法人神戸医療産業都市推進機構 多能性幹細胞の分化能の予測方法及びそのための試薬
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US20190062711A1 (en) * 2017-08-25 2019-02-28 So Young Life Sciences Corporation Use Of Phosphorylated TBeta4 And Other Factors To Generate Human Induced Pluripotent Stem Cells
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
JP7140400B2 (ja) 2017-10-17 2022-09-21 国立大学法人京都大学 多能性幹細胞から人工神経筋接合部を得る方法
KR101810014B1 (ko) 2017-10-23 2018-01-18 차의과학대학교 산학협력단 히스톤 데아세틸라제 저해제 및 골 형성 단백질 경로 차단제를 이용한 인간-유래의 체세포로부터 역분화 만능 줄기세포의 제조방법
KR101810008B1 (ko) 2017-10-23 2018-01-18 차의과학대학교 산학협력단 역분화-증진제를 이용한 인간-유래의 체세포로부터 역분화 만능 줄기세포의 제조방법
KR101998633B1 (ko) * 2017-10-31 2019-07-11 가톨릭관동대학교산학협력단 엘립티신의 줄기세포의 연골세포로의 분화 유도 용도
CN108624562B (zh) * 2018-05-18 2021-11-02 首都医科大学附属北京朝阳医院 一种制备肿瘤干细胞的方法及其专用试剂盒
KR102158783B1 (ko) * 2018-06-18 2020-09-22 한국생명공학연구원 세포 리프로그래밍 조성물 및 이를 이용한 유도만능줄기세포의 제조방법
US12391739B2 (en) 2018-07-13 2025-08-19 Kyoto University Method for producing gamma delta T cells
EP3824912A4 (en) 2018-07-19 2022-04-20 Kyoto University PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE
JP7357369B2 (ja) 2018-07-23 2023-10-06 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
JP7016102B2 (ja) 2018-12-06 2022-02-04 キリンホールディングス株式会社 Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤
JP7224001B2 (ja) 2018-12-21 2023-02-17 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
WO2020138371A1 (ja) 2018-12-26 2020-07-02 キリンホールディングス株式会社 改変ｔｃｒ及びその製造方法
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ，インク． Ｔ細胞疲弊を処置するための組成物および方法
JP7700673B2 (ja) 2019-05-15 2025-07-01 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
EP3974519A4 (en) 2019-05-20 2023-07-12 Ajinomoto Co., Inc. EXPANSION CULTURE METHOD FOR CARTILAGE OR BONE PRECURSOR CELLS
JP7699552B2 (ja) 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
WO2021015228A1 (ja) * 2019-07-25 2021-01-28 富士フイルム株式会社 特定の分化細胞の製造方法
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN112301052A (zh) 2019-08-01 2021-02-02 浙江霍德生物工程有限公司 一种通过体细胞重编程制备诱导多功能干细胞的方法
US20230030814A1 (en) 2019-12-12 2023-02-02 National University Corporation Chiba University Freeze-Dried Preparations Comprising Megakaryocytes and Platelets
KR102087084B1 (ko) * 2020-02-03 2020-03-10 주식회사 이에이치엘바이오 항노화인자를 발현하는 지방유래 줄기세포의 대량 배양방법
CA3170142A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tfgb antagonist prodrugs useful in the treatment of cancer and methods thereof
CN115427555A (zh) 2020-02-28 2022-12-02 武田药品工业株式会社 由多能干细胞产生自然杀伤细胞的方法
EP4170020A4 (en) 2020-06-17 2025-01-22 Kyoto University IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
EP4180514A4 (en) 2020-07-20 2024-09-04 Aichi Medical University COMPOSITION FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, MEDIUM FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, METHOD FOR MAINTENANCE CULTURE IN UNDIFFERENTIATED STATE OF PLURIPOTENT CELLS, AND METHOD FOR PRODUCING PLURIPOTENT CELLS
WO2022039279A1 (ja) 2020-08-18 2022-02-24 国立大学法人京都大学 ヒト始原生殖細胞／ヒト始原生殖細胞様細胞の維持増幅方法
JPWO2022196714A1 (enExample) 2021-03-17 2022-09-22
EP4331673A4 (en) 2021-04-30 2025-06-25 Riken Cord-like aggregates of retinal apigment epithelial cells, device and method of manufacture for the production thereof, and therapeutic agent comprising said cord-like aggregates
JPWO2022255489A1 (enExample) 2021-06-04 2022-12-08
CA3222761A1 (en) 2021-06-10 2022-12-15 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
WO2022264033A1 (en) 2021-06-15 2022-12-22 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
WO2023283631A2 (en) * 2021-07-08 2023-01-12 The Broad Institute, Inc. Methods for differentiating and screening stem cells
WO2023286834A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞
WO2023286832A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞の製造方法
JPWO2023017848A1 (enExample) 2021-08-11 2023-02-16
JPWO2023074648A1 (enExample) * 2021-10-25 2023-05-04
CN118265792A (zh) 2021-11-11 2024-06-28 希里欧斯株式会社 基因修饰多能干细胞、来自其的免疫活性细胞、它们的制造方法和它们的用途
EP4477746A4 (en) 2022-02-09 2026-02-18 Racthera Co Ltd METHOD FOR EVALUATING THE DIFFERENTIATION POTENTIAL OF CELLS IN A CULTURE BROTH IN THE DIFFERENCE OF MULTIPOTENTED STEM CELLS INTO NEURAL CELLS OF THE MENSCEPHAL FLOOR PLAQUE REGION
CN116694551A (zh) * 2022-02-24 2023-09-05 清华大学 诱导性成熟肝脏细胞及其制备的方法
WO2023210713A1 (ja) 2022-04-27 2023-11-02 国立大学法人京都大学 心外膜細胞再生促進剤および心外膜細胞の再生促進方法
CN114702591B (zh) * 2022-05-17 2022-09-23 诺赛联合(北京)生物医学科技有限公司 成体细胞衍生的类器官制备技术
US20250376727A1 (en) 2022-06-10 2025-12-11 Kyoto University Detection method and detection reagent for undifferentiated pluripotent stem cells
WO2024078118A1 (en) * 2022-10-12 2024-04-18 Peking University Chemical reprogramming and pluripotent stem cells
KR102887911B1 (ko) 2022-11-04 2025-11-19 건국대학교 글로컬산학협력단 분화된 세포의 유도만능줄기세포로의 리프로그래밍 효율 증진 방법
CN115772495B (zh) * 2022-12-02 2025-05-16 上海交通大学医学院附属第九人民医院 一种诱导胚胎干细胞定向分化为外胚层软骨祖细胞的培养基、方法及用途
WO2024248023A1 (ja) 2023-05-29 2024-12-05 京都府公立大学法人 視交叉上核オルガノイドの製造方法
EP4722345A1 (en) 2023-05-29 2026-04-08 Riken Method for maturing cardiomyocytes, and method for producing matured cardiomyocytes
JPWO2024248157A1 (enExample) 2023-05-31 2024-12-05

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
EP0981352B8 (en) 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
JP3626206B2 (ja) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ６及びその使用
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
USH1963H1 (en) 1998-01-16 2001-06-05 Dresser Industries, Inc. High pressure differential electrical connector
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
WO2000005344A1 (en) 1998-07-24 2000-02-03 The Carnegie Institution Of Washington METHOD FOR MAINTENANCE AND PROPAGATION OF GERMLINE STEM CELLS USING MEMBERS OF THE TGF-β FAMILY OF GROWTH FACTORS
GB9819912D0 (en) * 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
DE69924641D1 (de) 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
AU2002330077A1 (en) * 2001-09-21 2003-04-01 University Of Rochester Circadian control of stem/progenitor cell self-renewal and differentiation and of clock controlled gene expression
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ATE306810T1 (de) * 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
MXPA05003431A (es) 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
AU2004212490B2 (en) 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
WO2005033298A1 (ja) 2003-10-03 2005-04-14 Keiichi Fukuda 幹細胞から心筋細胞を分化誘導する方法
GB2407048B (en) 2003-10-15 2007-07-11 Biotrace Internat Plc Laboratory apparatus
WO2005038010A2 (en) 2003-10-16 2005-04-28 The University Court Of The University Of Edinburgh Control of es cell self-renewal and lineage specification, and medium therefor
US20070141703A1 (en) 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
JP5102030B2 (ja) 2004-08-13 2012-12-19 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ヒト胚性幹細胞における自己再生および分化のための組成物および方法
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
US20060182724A1 (en) 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells
US7601699B2 (en) * 2005-08-01 2009-10-13 Nupotential, Inc. Production of reprogrammed cells with restored potential
CA2621161A1 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
WO2007056163A2 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
GB2445706A (en) * 2005-11-11 2008-07-16 Univ Edinburgh Reprogramming and genetic modification of cells
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
JP5024049B2 (ja) 2005-12-16 2012-09-12 株式会社明電舎 真空コンデンサ
GB0601538D0 (en) * 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
US20090186076A1 (en) 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP1999249B8 (en) 2006-03-30 2012-02-15 The University Court Of The University of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
WO2007130474A2 (en) 2006-05-02 2007-11-15 Wisconsin Alumni Research Foundation Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
GB2437737B (en) 2006-05-04 2008-07-09 Access Products Ltd Scaffolding
CA2656398A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2044056B1 (en) 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
CA2675445C (en) 2007-01-17 2014-11-04 Wisconsin Alumni Research Foundation Improved culture of stem cells
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
WO2008094597A2 (en) 2007-01-30 2008-08-07 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
WO2008105630A1 (en) 2007-02-27 2008-09-04 Procell Therapeutics Inc. Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells
ES2703592T3 (es) 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
US8956866B2 (en) * 2007-04-18 2015-02-17 Hadasit Medical Research Services And Development Ltd. Retinal pigment epithelial cells differentiated from embryonic stem cells with nicotinamide and activin A
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
DK2173863T3 (en) 2007-06-29 2019-01-21 Fujifilm Cellular Dynamics Inc Automated method and apparatus for embryonic stem cell culture
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP2198011B1 (en) * 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
WO2009073523A2 (en) 2007-11-29 2009-06-11 Children's Hospital Of Orange County De-differentiation of human cells
EP2224940A1 (en) 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
WO2009067756A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
WO2009082184A2 (en) 2007-12-26 2009-07-02 Posdata Co., Ltd. Method for determining spurious and wireless communication system applying that method
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
JP6093110B2 (ja) 2008-12-17 2017-03-08 ザ スクリプス リサーチ インスティテュート 幹細胞の作製と維持
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
WO2010137348A1 (en) 2009-05-29 2010-12-02 Keio University Method for selecting clone of induced pluripotent stem cells
WO2011016588A1 (en) 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US9005968B2 (en) 2009-10-16 2015-04-14 The Scripps Research Institute Induction of pluripotent cells
EP2542669B1 (en) 2010-03-05 2015-01-21 Texas Heart Institute Ets2 and mesp1 generate cardiac progenitors from fibroblasts
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation

Also Published As

Publication number Publication date
JP6321733B2 (ja) 2018-05-09
WO2009117439A3 (en) 2009-12-30
WO2009117439A2 (en) 2009-09-24
JP2015119714A (ja) 2015-07-02
CN102027105B (zh) 2015-03-11
BRPI0908708A2 (pt) 2019-09-24
CA2718904C (en) 2017-01-03
JP2021143194A (ja) 2021-09-24
JP7642712B2 (ja) 2025-03-10
US20180171303A1 (en) 2018-06-21
EP3409762A1 (en) 2018-12-05
US9534205B2 (en) 2017-01-03
EP2955222B1 (en) 2018-09-12
JP2023101613A (ja) 2023-07-21
CA2718904A1 (en) 2009-09-24
AU2009225665B2 (en) 2014-12-04
RU2010139426A (ru) 2012-04-27
EP2955222A1 (en) 2015-12-16
CN102027105A (zh) 2011-04-20
US9771563B2 (en) 2017-09-26
SG10201808863UA (en) 2018-11-29
US20170081640A1 (en) 2017-03-23
US20160369244A1 (en) 2016-12-22
US9540615B2 (en) 2017-01-10
IL208144B (en) 2018-10-31
US20100233804A1 (en) 2010-09-16
US9394524B2 (en) 2016-07-19
ZA201006683B (en) 2011-11-30
SG10201607710UA (en) 2016-11-29
MX2010010165A (es) 2010-11-25
EP2279243B1 (en) 2016-01-06
JP2025015628A (ja) 2025-01-30
US20130273536A1 (en) 2013-10-17
AU2009225665B9 (en) 2015-01-15
JP2016185172A (ja) 2016-10-27
EP2279243A4 (en) 2011-06-29
CN104694570A (zh) 2015-06-10
US20110110899A1 (en) 2011-05-12
US9926533B2 (en) 2018-03-27
EP4578941A3 (en) 2025-10-08
CN104694570B (zh) 2019-07-16
JP6899792B2 (ja) 2021-07-07
IL208144A0 (en) 2010-12-30
JP2011517560A (ja) 2011-06-16
EP2279243A2 (en) 2011-02-02
US20100267141A1 (en) 2010-10-21
JP5951254B2 (ja) 2016-07-13
HK1209457A1 (zh) 2016-04-01
US20180002671A1 (en) 2018-01-04
SG188904A1 (en) 2013-04-30
US9068170B2 (en) 2015-06-30
AU2009225665A1 (en) 2009-09-24
KR101679082B1 (ko) 2016-11-23
KR20100124335A (ko) 2010-11-26
JP2018104473A (ja) 2018-07-05
SG10202103401QA (en) 2021-05-28
JP7286710B2 (ja) 2023-06-05
EP4578941A2 (en) 2025-07-02
HK1151559A1 (zh) 2012-02-03

Similar Documents

Publication Publication Date Title
JP7642712B2 (ja) 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
AU2022203937B2 (en) Combined chemical and genetic approaches for generation of induced pluripotent stem cells
HK40121636A (en) Combined chemical and genetic approaches for generation of induced pluripotent stem cells
HK40001509A (en) Combined chemical and genetic approaches for generation of induced pluripotent stem cells
HK1209457B (zh) 用於產生誘導的多能幹細胞的組合化學遺傳方法
HK1151559B (en) Combined chemical and genetic approaches for generation of induced pluripotent stem cells